Dynamic pharmacogenetic models in anticoagulation therapy.
This article demonstrates how a dynamic clinical-support tool can guide individualized drug therapy. We use the drug warfarin as a model to demonstrate how pharmacogenetics when combined with fundamental principles of pharmacokinetic and pharmacodynamics can provide a powerful decision-support tool to optimize personalized therapeutics.
Bon Homme
Marjorie
M
Department of Pathology and Laboratory Medicine, University of Louisville, 501 South Floyd Street, MDR-218, Louisville, KY 40202, USA.
Reynolds
Kristen K
KK
Valdes
Roland
R
Linder
Mark W
MW
D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D065729:Cytochrome P-450 CYP2C9; D020000:Decision Support Systems, Clinical; D005838:Genotype; D006801:Humans; D019934:International Normalized Ratio; D006899:Mixed Function Oxygenases / Q000235:genetics; D008962:Models, Theoretical; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D064417:Vitamin K Epoxide Reductases; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000925:Anticoagulants; D014859:Warfarin; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D064417:Vitamin K Epoxide Reductases